Get notified when OGN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Fraud / investigation

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • SEC Investigation Into Nexplanon Sales (new) — The Company disclosed an SEC investigation into Nexplanon sales practices, which could lead to regulatory action and significant costs.
NYSE: OGN Organon & Co. 10-Q

Organon's Q3 revenue fell 1.7% to $1.57B, while net income rose 2.5% to $164.0M.

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 10, 2025 · ~1 min read

Key Changes

  • high

    The pending acquisition by Sun Pharma for $14.00 per share in cash, approved by stockholders in July, is expected to close by early 2027.

    view on EDGAR →
  • high

    Revenue fell 1.7% to $1.57B in Q3, with declines in Nexplanon, Ontruzant, and Jada, and growth in Hadlima, Bildyos/Bilprevda, and Emgality.

    view on EDGAR →
  • high

    Net income rose 2.5% to $164.0M, while interest expense fell 17.2% to $106.0M.

    view on EDGAR →

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.

Partner

Trade OGN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Nov 2, 2026 · How we verify